Reviewer #1 (Public review):
Summary:
Weiss et. al. seek to delineate the mechanisms by which antigen-specific CD8+ T cells outcompete bystanders in the epidermis when active TGF-b is limiting, resulting in selective retention of these cells and more complete differentiation into the TRM phenotype.
Strengths:
They begin by demonstrating that at tissue sites where cognate antigen was expressed, CD8+ T cells adopt a more mature TRM transcriptome than cells at tissue sites where cognate antigen was never expressed. By integrating their scRNA-Seq data on TRM with the much more comprehensive ImmGenT atlas, the authors provide a very useful resource for future studies in the field. Furthermore, they conclusively show that these "local antigen-experienced" TRM have increased proliferative capacity and that TCR avidity during TRM formation positively correlates with their future fitness. Finally, using an elegant experimental strategy, they establish that TCR signaling in CD8+ T cells in the epidermis induces TGFBRIII expression, which likely contributes to endowing them with a competitive advantage over antigen-inexperienced TRM.
Weaknesses:
The main weakness in this paper lies in the authors' reliance on a single experimental model to derive conclusions on the role of local-antigen during the acute phase of the response by comparing T cells in model antigen-vaccinia virus (VV-OVA) exposed skin to T cells in contralateral skin exposed to DNFB 5 days after the VV-OVA exposure. In this setting, antigen-independent factors may contribute to the difference in CD8+ T cell number and phenotype at the two sites. For example, it was recently shown that very early memory precursors (formed 2 days after exposure) are more efficient at seeding the epithelial TRM compartment than those recruited to skin at later times (Silva et al, Sci Immunol, 2023). DNFB-treated skin may therefore recruit precursors with reduced TRM potential. In addition, TRM-skewed circulating memory precursors have been identified (Kok et al, JEM, 2020), and perhaps VV-OVA exposed skin more readily recruits this subset compared to DNFB-exposed skin. Therefore, when the DNFB challenge is performed 5 days after vaccinia virus, the DNFB site may already be at a disadvantage in the recruitment of CD8+ T cells that can efficiently form TRM. In addition, CD8+ T cell-extrinsic mechanisms may be at play, such as differences in myeloid cell recruitment and differentiation or local cytokine and chemokine levels in VV-infected and DNFB-treated skin that could account for differences seen in TRM phenotype and function between these two sites. Although the authors do show that providing exogenous peptide antigen at the DNFB-site rescues their phenotype in relation to the VV-OVA site, the potential antigen-independent factors distinguishing these two sites remain unaddressed. In addition, there is a possibility that peptide treatment of DNFB-treated skin initiates a second phase of priming of new circulatory effectors in the local-draining lymph nodes that are then recruited to form TRM at the DFNB-site, and that the effect does not solely rely on TRM precursors at the DNFB-treated skin site at the time of peptide treatment. These concerns are somewhat alleviated by the fact that in a prior publication (PMID: 33212014), the group has already established a role for local antigen encounter in skin in a setting where they compared contralateral ears infected with VV-OVA and VV expressing an irrelevant antigen.
Secondly, although the authors conclusively demonstrate that TGFBRIII is induced by TCR signals and required for conferring increased fitness to local-antigen experienced CD8+ TRM compared to local antigen-inexperienced cells, this is done in only one experiment, albeit repeated 3 times. The data suggest that antigen encounter during TRM formation induces sustained TGFBRIII expression that persists during the antigen-independent memory phase. It remains however, unclear why only antigen encounter in skin, but not already in the draining lymph nodes, induces sustained TGFBRIII expression. Further characterizing the dynamics of TGFBRIII expression on CD8+ T cells during priming in draining lymph nodes and over the course of TRM formation and persistence may shed more light on this question. Probing the role of this mechanism at other sites of TRM formation would also further strengthen their conclusions and enhance the significance of this finding.
A minor caveat of the study pertains to the use of FTY720 to block T cell egress from lymphoid tissues and thereby prevent a contribution of circulating memory OT-I T cells to the local recall response in skin. Since the half-life of FTY720 is less than a day in mice, its effects wear off rapidly. In their experiments, the authors discontinued treatment at the time of re-challenge, which may have allowed circulating T cells to contribute to the local recall response in skin, limiting the interpretability of the results somewhat. This concern is alleviated by the use of a second method (anti-Thy1.1-depleting antibodies) to eliminate circulating memory cells. For the benefit of readers intending to use this experimental strategy, it should however, be noted that FTY720 needs to be dosed continually (e.g. 3x/week at an appropriate dose) in order to sustain its effect.